sprite-preloader
Anzeige
Mehr »
Mittwoch, 13.12.2017 Börsentäglich über 12.000 News von 573 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A1XA8R ISIN: DK0060534915 Ticker-Symbol: NOVC 
Aktie:
Branche
Pharma
Aktienmarkt
OMX Copenhagen 20
STOXX Europe 50
1-Jahres-Chart
NOVO NORDISK A/S Chart 1 Jahr
1-Woche-Intraday-Chart
NOVO NORDISK A/S 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
44,991
45,155
18:10
44,946
45,075
18:44
21.04.2017 | 16:40
(206 Leser)
Schrift ändern:
(1 Bewertungen)

GlobeNewswire (Europe)·Mehr Nachrichten von GlobeNewswire (Europe)

Bagsværd, Denmark, 21 April 2017 - At Novo Nordisk's Annual General Meeting on 23 March 2017, it was decided to reduce the company's B share capital from DKK 402,512,800 to DKK 392,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each. 

Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled nominally DKK 10,000,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 500,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 392,512,800.

The reduction in the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.

Further information

Media:    
Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com (mailto:amhg@novonordisk.com)
 

Investors:
   
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com (mailto:phak@novonordisk.com)
Hanna Ögren
Anders Mikkelsen
Kasper Veje (US)
+45 3079 8519
+45 3079 4461
+1 609 235 8567
haoe@novonordisk.com (mailto:haoe@novonordisk.com)
armk@novonordisk.com (mailto:armk@novonordisk.com)
kpvj@novonordisk.com (mailto:kpvj@novonordisk.com)

Company announcement No 29 / 2017 


CA170421_Kapitalnedsættelse_UK (http://hugin.info/2013/R/2097772/794349.pdf)



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire


© 2017 GlobeNewswire (Europe)